Trade-Ideas: Myriad Genetics (MYGN) Is Today's Post-Market Leader Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Myriad Genetics ( MYGN) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Myriad Genetics as such a stock due to the following factors:

  • MYGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $52.0 million.
  • MYGN is up 5.3% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MYGN with the Ticky from Trade-Ideas. See the FREE profile for MYGN NOW at Trade-Ideas

More details on MYGN:

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. MYGN has a PE ratio of 15.5. Currently there are 3 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 10 rate it a hold.

The average volume for Myriad Genetics has been 2.3 million shares per day over the past 30 days. Myriad has a market cap of $2.4 billion and is part of the services sector and diversified services industry. The stock has a beta of 0.93 and a short float of 54.4% with 27.76 days to cover. Shares are up 63% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 14.9%. Since the same quarter one year prior, revenues rose by 36.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • MYGN has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 6.55, which clearly demonstrates the ability to cover short-term cash needs.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, MYRIAD GENETICS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for MYRIAD GENETICS INC is currently very high, coming in at 88.39%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 24.67% is above that of the industry average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

37 Stocks That Will Probably Keep Nosediving

37 Stocks That Will Probably Keep Nosediving

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma